Thermo Fisher Scientific Showcases Diagnostics Solutions Designed to Meet Evolving Global Healthcare Demands at ADLM 2025
'Our solutions harness our scientific expertise to enhance care by enabling earlier and more precise detection and diagnosis. In partnership with our customers, we're working every day to bring better, faster and safer diagnostics to all patients,' said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. 'At Thermo Fisher, we are committed to advancing diagnostics that address today's most pressing global health challenges by boosting efficiency and reducing overall laboratory costs — ultimately driving more optimal patient care.'
Harnessing Innovation for Quality Assurance, Efficiency and Sustainability in the Clinical Lab
Clinical laboratories rely on quality assurance programs (QAPs) to ensure test result accuracy, which is essential for proper diagnosis and treatment. In resource-limited settings, a QAP that delivers quick, actionable insights can ease operational bottlenecks, improve workflow efficiency and enhance data-driven decisions. Thermo Fisher's new LabLink360 is a next-generation QAP software designed to help enhance patient safety, reduce errors and elevate healthcare quality. It features Sigma-metric analysis, a global benchmarking tool that helps labs assess performance and optimize quality control parameters based on results.
Thermo Fisher also recently launched the Thermo Scientific MAS Omni•CORE ™ Max load-and-go quality controls (QC) to help simplify and automate lab workflows, allowing lab technicians to be more efficient and focus more on delivering fast and accurate patient results. The Omni•CORE Max QCs are part of a portfolio of QCs for clinical diagnostic testing, including the MAS Diabetes Max, which can help labs reduce daily QC bottles by up to 54% and lot-to-lot validations by up to 77%.**
Beyond supporting the improved efficiency of laboratories, Thermo Fisher is also committed to supporting customers' sustainability initiatives. While most labs print patient results, QC, calibrations and other instrument data and place them in storage, this practice contributes to a staggering environmental impact. The company will present a poster and a micro-lecture explaining the transformative benefits of transitioning to a paperless laboratory environment.
Targeting Unmet Diagnostic Needs
Approximately 85% of patients in the U.S. receive cancer care in community settings. However, these sites have historically lacked consistent access to rapid and reliable next-generation sequencing, which is playing a growing role in informing precision oncology treatment decisions. At ADLM, the company will present its rapid NGS solution, the Oncomine Dx Express Test on the Ion Torrent Genexus Integrated Sequencer. Available as both an RUO solution and for clinical use on the Genexus Dx System, more care teams can now access NGS results in as little as 24 hours*** to help make more informed treatment recommendations for their patients, while also sparing patients from unnecessary delays, procedures and uncertainty.
Also helping expand vital testing the company will highlight its PreClara™ Ratio,**** cleared in 2023 and previously known as B·R·A·H·M·S™ sFlt-1/PlGF KRYPTOR™ Test System, which offers clarity in assessing the risk of developing preeclampsia with severe features in hospitalized pregnant women within two weeks of testing. As the first FDA-cleared biomarker test for preeclampsia risk assessment, the PreClara Ratio provides reliable, quantifiable results with excellent analytical and clinical performance. When combined with other laboratory tests and standard clinical assessment, the PreClara Ratio may enable more informed clinical decisions, with the aim of improving health outcomes for both mothers and their babies.
Thermo Fisher will also highlight its EXENT ® Solution, a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The EXENT Solution enables more sensitive analytical methods that can differentiate between patient subsets without requiring invasive bone marrow biopsy techniques too early. It is currently available for clinical use in Brazil, Belgium, France, Germany, Italy, the Netherlands, New Zealand, Spain, the United Kingdom, Switzerland and Australia.
Thermo Fisher is also presenting its latest solutions for allergy and autoimmune diagnostics, oncology, women's health and quality control testing. In the booth, attendees can engage with a series of dynamic micro-lectures designed to advance industry knowledge and clinical expertise. These sessions cover a wide range of diagnostic topics and innovations, offering valuable insights into improving testing efficiency, patient outcomes and disease detection strategies.
For more information on Thermo Fisher's activities at ADLM, please visit www.thermofisher.com/adlm or conference booth (2812) to experience the full breadth of Thermo Fisher's diagnostic solutions.
* Not yet commercially available.
** Will vary for each laboratory depending on the configuration. Data on file.
***Timing varies by number of samples and type of run.
****Brand trademarked in the U.S. only.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
3 hours ago
- Time Business News
Ford: A Timeless Journey of Innovation, Strength, and Legacy
Few automotive brands carry the weight of history and innovation quite like Ford. It's more than just a company—it's a global icon, a symbol of progress, and a trusted name woven into the fabric of modern society. From the roaring engines of classic muscle cars to the silent hum of next-gen electric vehicles, Ford represents a legacy of freedom, reliability, and bold vision. For over a century, Ford has stood as a pioneer of both industry and imagination. Whether you're cruising down a coastal highway or hauling heavy loads across rugged terrain, Ford drives dreams forward—generation after generation. In 1903, a visionary named Henry Ford changed the course of transportation forever. He didn't just build cars—he built a movement. Ford believed that every individual, not just the wealthy, deserved access to mobility. This dream gave birth to the Model T, the car that put the world on wheels. What truly set Ford apart was the introduction of the moving assembly line in 1913. This groundbreaking innovation reduced manufacturing time, lowered costs, and allowed Ford to pay workers fair wages. It wasn't just a business decision—it was a social revolution. In many ways, Ford helped shape the modern middle class. What began in a modest Detroit workshop has grown into a global powerhouse. Today, Ford operates in more than 100 countries, with production plants, design studios, and dealerships around the globe. Each region sees its piece of the Ford experience—from compact cars in Asia to heavy-duty trucks in the Americas. But despite its global presence, Ford maintains its core identity: durability, innovation, and customer trust. That's why you'll see a Ford at a dusty construction site in Texas, a rally course in Kenya, or a city street in London—proving that Ford is truly built for every road, every driver. Ford's legacy is one of constant reinvention. While honoring its heritage, Ford has always had one foot in the future. Recent years have seen an incredible wave of technological innovation: Ford Co-Pilot360™ : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. : A suite of advanced driver-assist features like automatic emergency braking, blind-spot monitoring, and lane-keeping systems—all designed to keep drivers safer and more confident behind the wheel. SYNC Infotainment System : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. : Voice-activated technology, navigation, Apple CarPlay, Android Auto, and cloud-connected features bring cutting-edge tech to your fingertips. FordPass™ App: A smartphone gateway to remote start, lock/unlock, locate your vehicle, schedule service appointments, and more. Innovation isn't a trend for Ford—it's part of its DNA. The automotive world is shifting, and Ford is leading the charge—literally. With a multi-billion-dollar investment in electric vehicle (EV) infrastructure, Ford is committed to a cleaner, brighter, and more efficient future. Mustang Mach-E : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. : This all-electric SUV combines the soul of the iconic Mustang with the sustainability of the future's sleek, silent—and pure adrenaline. F-150 Lightning : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. : The beloved pickup, reborn as an all-electric powerhouse. With dual motors, instant torque, and even the ability to power your home, it's redefining what a truck can be. E-Transit Van: Designed for commercial use, this EV delivers zero-emissions transport without sacrificing payload or functionality. Ford is more than ready for tomorrow—it's building it today. If there's one phrase that perfectly defines Ford's spirit, it's 'Built Ford Tough.' Ford's lineup of trucks—especially the iconic F-Series—has been trusted by hard-working individuals for generations. The Ford F-150, in particular, is the best-selling vehicle in the United States for over 40 years. It's not just popular; it's legendary. With exceptional towing capacity, military-grade aluminum alloy construction, hybrid powertrain options, and rugged styling, it's built for those who demand power, performance, and perseverance. Ford understands that authentic leadership means protecting the world we share. That's why sustainability is a core focus: Committed to carbon neutrality by 2050 Manufacturing plants powered by renewable energy Use of recycled and sustainable materials in new vehicle production in new vehicle production Innovation in battery technology and EV charging infrastructure Ford isn't just adapting to environmental responsibility—it's setting the standard. For millions, owning a Ford is more than transportation—it's a relationship. It's the car that taught your teenager to drive, the truck that hauled your first home, the Mustang that turned heads, or the van that took your family on summer road trips. Ford vehicles are in the photos of your memories, in the heart of your journeys, and in the conversations passed down from one generation to the next. This emotional bond is what makes Ford timeless. From Steve McQueen's 1968 Mustang in Bullitt to Will Smith's futuristic Ford GT in I, Robot , Ford has become a pop culture icon. Songs, movies, video games—you'll find Ford roaring across them all. That's because Ford is more than a car—it's a character, a symbol, and a source of inspiration. With over a century of legacy, innovation, and trust, Ford remains a brand like no other. It's a company that stays true to its roots while courageously reimagining the future. Whether you're a die-hard Mustang enthusiast, a rugged F-150 driver, or a first-time EV owner, Ford welcomes you with open arms—and an open road. Because with Ford, the drive never ends. TIME BUSINESS NEWS
Business Upturn
4 hours ago
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
4 hours ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
